Medline rises in Nasdaq debut, tops 2025 IPOs with $46B valuation

Medline shares rose 20.7% in their hotly anticipated New York debut today, valuing the medical supply giant at $46 billion in the largest U.S. initial public offering since Rivian’s 2021 listing, capping a strong year for new listings and fueling optimism for 2026.

See the original article at: Honolulu Star-Advertiser